Small Cap Feast

Small Cap Feast – 05 September 2019

Dish of the Day:

No Joiners Today

Off the Menu:

No Leavers Today

What’s Cooking in the IPO Kitchen?


Bracken Trading — The Group undertakes its main trade of lending as well as electricity generation through the operation of two solar farms. Admission on the 09/09/2019

WORLD HIGH LIFE—The Investment Vehicle is to identify investment opportunities and acquisitions in legal Medicinal Cannabis, Hemp and CBD wellness sectors. The Company has raised £2,398,309 through three issues of Ordinary Shares to private subscribers.

Breakfast Buffet

Location Sciences (LSAI) 3.1p £10m

Location Sciences, the leading mobile location data and intelligence expert, announces a new 18-month contract with Blis, the global leader in real-world intelligence. Blis is the first global location intelligence company to embrace independent verification of data quality. 

Blis will use Verify, Location Sciences’ proprietary location verification platform, to provide independent, media-agnostic analysis and authentication of its location-targeted advertising data.

Blis and Location Sciences are coming together as two independent companies with a common goal for more transparency and data integrity in the advertising industry. At a time when clients are looking for more accountability from their technology partners, and increased transparency for their digital activity, this alliance paves the way for substantial improvements in data accuracy. Clients are demanding third-party verification and Location Sciences’ Verify product can now provide that independent layer of validation and assurance for Blis’ global client base.

Morses Club (MCL) 126p £163m

Morses Club PLC, the UK’s second largest home collected credit lender, provides the following trading update for the 27-week period to 31 August 2019. (Please note that the prior year comparison is a 26-week period).

The Company has performed well in the period with strong progress on the development of our product diversification strategy. Trading conditions in our core HCC market remain in line with the Board’s expectations, with total credit issued remaining broadly at the same level when compared to H1 2019 at £85.5m (H1 2019: £85.7m). Cash collections were up 5% compared to H1 2019 (H1 2019: 11.9%), and impairments expected to remain within the Company’s IFRS 9 guidance range. Consistent with previous years, our results are expected to be fairly evenly split between each half, with the usual slight seasonal uplift in H2.

Total customer numbers of 224,000 at 31 August 2019 have remained largely stable (H1 2019: 229,000), with the gross loan book also remaining stable with 0.2% growth (H1 2019: 6.1% growth).

Altus Strategies (ALS) 4.9p £8.45m

Altus Strategies Plc, the Africa focused project and royalty generator, announces that it has defined Diba SW, a potentially significant new prospect at the Diba gold project. Diba is strategically located 13km south of the multi-million ounce Sadiola gold mine, in the world renowned ‘Kenieba Window’ gold belt in the west of the Republic of Mali.


Diba SW prospect defined by 1.2km long discontinuous soil anomaly.

Prospect located 0.5km along strike of the historical Diba resource area

Anomaly occurs along the flank of a topographic ridge and is coincident with a geophysical anomaly

High grade historical drill intersections at Diba of 5.02g/t Au over 20.0m and 5.36 g/t over 13m

Diba hosts a historical near surface gold resource (see “Diba Project: Historic resource” and “Cautionary note regarding historic data”

Ceres Power Holdings (CWR) 191p £283m

Ceres Power, a world leading developer of next generation fuel cell technology and Weichai Power, one of the leading automobile and equipment manufacturing companies in China, announce they have completed the development of a first prototype range extender for Chinese electric buses.

Following a successful technology transfer and the licensing of system-level technology from Ceres to Weichai Power, the combined team has produced a first prototype 30kW SteelCell® Solid Oxide Fuel Cell range extender system, which met the required technical performance criteria, for demonstration in an Electric City bus utilising widely available Compressed Natural Gas fuel. 

This marks the completion of the initial Joint Development Agreement between Ceres and Weichai, the first step in the collaboration first announced in May 2018 and cements a strong working relationship between the two companies.

Alumasc Group (ALU) 91.5p £31.44m

Alumasc (ALU.L), the premium building products, systems and solutions Group, announces results for the year ended 30 June 2019.

Group revenues up 4% to £90.1m (2018: £87.0m)

Underlying profit before tax £5.6m (2018: £6.0m) reflecting the previously reported performance from Levolux

Basic earnings per share of 10.1 pence (2018: 12.0 pence)

Maintained total dividend for year of 7.35 pence (2018: 7.35 pence) reflecting the Board’s confidence in the future and positive impact of the recent restructuring actions

Net debt of £5.1m (2018: £4.8m)

Kibo Energy (KIBO) 0.85p £6m

Kibo Energy PLC, the multi-asset, Africa focused energy company, announced that it has signed a non-binding Power Purchase Term Sheet and a non-binding Coal Supply Term Sheet with Vale Mozambique, S.A. for the Benga Power Plant Project in Mozambique. Also see the RNS of 7 June 2019 in this regard.

PPTS signed with Vale for c.37% of the available power targeted for phase 1 generation at the BPPP. The Agreement highlights the urgent need for a reliable power source in the region

Inspiration Health (IHC) 59.5p £18.25m

Inspiration Healthcare Group plc, the global medical technology company, announced that it has today entered into a conditional agreement to acquire the entire issued share capital of Vio Holdings Limited, the holding company of VIOMEDEX Limited, for an aggregate consideration of £4.0 million on a cash free debt free basis.

VIOMEDEX, designs, manufactures and supplies single use respiratory products and sterile medical consumables, principally for the respiratory care market.

boohoo group plc (BOO) 282p £2,835m

boohoo group plc today announces a trading update for the first half of its financial year, where performance has been ahead of expectations with strong revenue growth driving operating leverage across key brands.

Consequently, the board now anticipates that results for the current financial year will be ahead of previous guidance, with Group sales growth now expected to be between 33% and 38% (against previous guidance of 25% to 30%). The board anticipates EBITDA margins for the financial year to remain at around 10% (in line with previous guidance), reflecting anticipated investments across the financial year into the three brands acquired by the Group in the first half.

Evgen Pharma (EVG) 17.25p £21.16m

Evgen Pharma, a clinical stage drug development company focused on the treatment of cancer and neurological conditions, announces that it has entered into a Memorandum of Understanding with Guy’s and St Thomas’ NHS Foundation Trust to advance the Company’s lead compound SFX-01, towards a clinical trial in patients diagnosed with Autism Spectrum Disorder.

Zambeef Products (ZAM) 6.12p £18.41m

Zambeef, the fully integrated food producer with operations in Zambia, Nigeria and Ghana, announces the appointment of Michael Mundashi as an Independent Non-Executive Director and Faith Mukutu as Chief Financial Officer and Executive Director, with immediate effect.

Head Chef:

Derren Nathan
0203 764 2344

*A corporate client of Hybridan LLP


This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.

The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).

Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.

This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.

Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.

Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.

MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.

Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.

If you would like to unsubscribe, please email with “unsubscribe me”.